Source comparison
Separate vials vs pre-mixed blends
The two research configurations documented on this site differ in a way that follows directly from everything above. Separate vials. Our CJC-1295 DAC 5 mg + ipamorelin 5 mg stack protocol keeps the compounds in separate vials. This is the only configuration th
This comparison does not assign a generated winner or score.
- The two research configurations documented on this site differ in a way that follows directly from everything above.
- Separate vials. Our CJC-1295 DAC 5 mg + ipamorelin 5 mg stack protocol keeps the compounds in separate vials. This is the only configuration that is pharmacologically coherent when the DAC molecule is involved, and the reason is arithmetic: the DAC molecule is dosed twice weekly and ipamorelin is dosed daily (see our ipamorelin dosage protocol guide for its documented figures). A twice-weekly compound and a daily compound cannot share a vial and a single schedule without one of them being wrong by a factor of three or four.
- Pre-mixed blends. A CJC-1295 + ipamorelin blend vial exists precisely because the no-DAC molecule and ipamorelin share a dosing frequency — both are short-acting, both are dosed daily. That shared cadence is what makes a fixed-ratio blend chemically sensible. This is the answer to the common query about “CJC-1295 ipamorelin 10 mg blend dosage per day”: a blend of that description is a no-DAC blend by structural necessity, and it is dosed daily. If a product is advertised as a “CJC-1295 + ipamorelin blend” with a weekly schedule, or as a DAC blend with a daily schedule, one of the two claims is wrong.
- The pairing is not purely a research-chemical phenomenon, and the regulatory record is oddly specific about it: FDA’s 2024 review notes that a US outsourcing facility reported compounding a multiple-ingredient injection powder containing CJC-1295 at 6 mg/mL and ipamorelin at 15 mg/mL in 2019 and 2020 — which form of CJC-1295 was not stated — and that no outsourcing facility has reported compounding any CJC-1295-containing product since 2020[11]. Note that even in a compounded product, nobody recorded which molecule was in the vial. The naming collision reaches all the way into the federal reporting system.
- The constraint of a blend is inflexibility: a 10 mg blend vial fixes the ratio of the two peptides permanently at whatever the manufacturer chose. The total drawn can be changed; the ratio cannot. Given that no trial has established what the ratio should be, that permanence encodes a manufacturer’s guess rather than a finding.